Compare iShares MSCI Hong Kong ETF (EWH) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs McKesson Corporation — how do they compare? iShares MSCI Hong Kong ETF trades at $22.06, while McKesson Corporation trades at $820.37 (market cap $93.23B). The key difference: McKesson Corporation pays a 0.41% dividend while iShares MSCI Hong Kong ETF pays none. Which is the better fit depends on your goals.
| EWH | MCK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $995.69 |
52-Week Low | $20.15 | $659.01 |
Market Cap | — | $93.23B |
Enterprise Value | — | $97.87B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH trades at $22.05, up 1.75% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF tracks Hong Kong equities, with recent momentum in Chinese tech stocks supporting performance. A dividend of $0.35 is scheduled for June 2026. Support and resistance cluster tightly around $22, indicating a critical price zone.
Outlook hinges on Hang Seng Index momentum and China's economic policies. Risks include regulatory scrutiny on Chinese firms and Asian market volatility. Analyst sentiment is mixed, with technical strength countered by valuation concerns in global markets.
McKesson (MCK) trades at $803.37, down 1.1% on the day, with technical indicators showing a neutral to bullish bias as the price sits near pivot point $805. The company demonstrates strong fundamental momentum with revenue growing from $264B in 2022 to $359.1B in 2025, and a consistent track record of beating earnings estimates in recent quarters. Analyst sentiment is overwhelmingly positive, with 80% recommending Buy and a consensus price target of $932.83, representing a 16% upside from current levels.
The outlook for MCK is favorable, supported by robust revenue growth, expanding profitability, and strong analyst conviction. Key opportunities include continued execution in specialty pharma and oncology services. Primary risks involve policy changes affecting healthcare distribution, intense industry competition, and execution challenges in integrating growth initiatives, which could pressure margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
